fbpx Skip to main content

MONDAY, Nov. 2, 2020 (HealthDay News) — The prevalence of masked asleep hypertension is high among U.S. adults, according to a study published online Oct. 28 in JAMA Cardiology.

Siling Li, from Columbia University in New York City, and colleagues estimated the prevalence of masked asleep hypertension among U.S. adults by using blood pressure (BP) thresholds from the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) and the 2017 American College of Cardiology-American Heart Association (ACC-AHA) BP guidelines. The analysis included 3,000 participants with 24-hour ambulatory BP monitoring (ABPM) and 17,969 participants in the 2011-2016 National Health and Nutrition Examination Survey without ABPM.

The researchers found that the estimated prevalence of masked asleep hypertension among U.S. adults was 18.8 percent (44.4 million U.S. adults) using the JNC7 guideline and 22.7 percent (53.7 million U.S. adults) using the 2017 ACC-AHA guideline criteria. Older adults (≥65 years; 24.4 percent), men (27.0 percent), non-Hispanic Black individuals (28.7 percent), those who were taking antihypertensives (24.4 percent), those who had masked daytime hypertension (44.7 percent), and those with diabetes (27.6 percent), obesity (24.3 percent), or chronic kidney disease (21.5 percent) had a higher prevalence of masked asleep hypertension using the 2017 ACC-AHA guideline. Using JNC7 guideline criteria, an estimated 11.9 percent of U.S. adults (28.2 million) had isolated masked asleep hypertension, as did an estimated 13.3 percent (31.5 million) using 2017 ACC-AHA guideline criteria.

“Future research should investigate the possible cardiovascular risk reduction and economic benefits of treating asleep hypertension,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

You May Also Like::  Inequities Seen in Accessing Telemedicine During COVID-19

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More